174 related articles for article (PubMed ID: 19198869)
1. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
[TBL] [Abstract][Full Text] [Related]
2. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
3. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
[TBL] [Abstract][Full Text] [Related]
4. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
5. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
6. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
[TBL] [Abstract][Full Text] [Related]
7. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ocular inflammatory disorders with daclizumab.
Papaliodis GN; Chu D; Foster CS
Ophthalmology; 2003 Apr; 110(4):786-9. PubMed ID: 12689903
[TBL] [Abstract][Full Text] [Related]
9. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
[TBL] [Abstract][Full Text] [Related]
10. [Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
Hernández Garfella ML; Díaz Llopis M; Salom Alonso D; Cervera Taulet E
Arch Soc Esp Oftalmol; 2004 Dec; 79(12):593-8. PubMed ID: 15627927
[TBL] [Abstract][Full Text] [Related]
11. Biological response modifier therapy for refractory childhood uveitis.
Gallagher M; Quinones K; Cervantes-Castañeda RA; Yilmaz T; Foster CS
Br J Ophthalmol; 2007 Oct; 91(10):1341-4. PubMed ID: 17556427
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.
Kiss S; Ahmed M; Letko E; Foster CS
Ophthalmology; 2005 Jun; 112(6):1066-71. PubMed ID: 15936442
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab for treatment of birdshot chorioretinopathy.
Sobrin L; Huang JJ; Christen W; Kafkala C; Choopong P; Foster CS
Arch Ophthalmol; 2008 Feb; 126(2):186-91. PubMed ID: 18268208
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
15. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
Ingle GR; Moudgil A; Vo A; Jordan SC
Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
[TBL] [Abstract][Full Text] [Related]
17. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.
Suelves AM; Arcinue CA; González-Martín JM; Kruh JN; Foster CS
Ophthalmology; 2013 Jun; 120(6):1201-9. PubMed ID: 23601800
[TBL] [Abstract][Full Text] [Related]
18. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
